Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 5Genitourinary 4Gastrointestinal 4Gynecologic 3Myeloid 2Thoracic 1Plasma cell 1Head & Neck 1Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 143fludarabine phosphate 130Busulfan 109Tacrolimus 94fludarabine 93Mycophenolic Acid 90Whole-Body Irradiation 84Peripheral Blood Stem Cell Transplantation 81Imatinib Mesylate 69Antilymphocyte Serum 67Cyclosporine 66Azacitidine 64Cytarabine 63Methotrexate 60Melphalan 60Filgrastim 50Granulocyte Colony-Stimulating Factor 40Decitabine 40Thiotepa 38thymoglobulin 34Stem Cell Transplantation 34Dasatinib 34Radiotherapy 33nilotinib 31ruxolitinib 28Cord Blood Stem Cell Transplantation 28venetoclax 26Clofarabine 25Specimen Handling 24Methylprednisolone 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × bryostatin 1 × Myeloid × Clear all
NCT00003171 2013-04-05

Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00136461 2011-03-10

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Dana-Farber Cancer Institute

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡